The Italian biotechnology industry has undergone extraordinary growth in large part due to excellent academic and industrial research and the ability of Italian companies to turn innovation into valuable products and technologies. Almost 500 biotech companies were active in Italy at the end of 2019, covering all fields of applications. Over half of these are dedicated biotech R&D firms.  

Market Facts

  • Rare disease and advanced therapy medicinal products are among areas of excellence of Italian biotechnology research.
  • 75% of Italy’s biotechnology companies are micro or small-sized organizations.

Italian Association for the Development of Biotechnology (Assobiotec)

Assobiotec, the Italian Association for the Development of Biotechnology, was born to foster, support and defend the development of biotechnology in all its various application fields, such as: human and animal healthcare (“red biotech”), agriculture and nutrition (“green biotech”), environment, processing industry, biomaterials, bioenergy, construction industry, restoration (“white biotech”).

Set up in 1986 within the Italian Federation of the Chemical Industry (Federchimica), Assobiotec represents companies and science & technology parks operating in Italy and involved in several sectors of life sciences.

Association’s resources

  • The Italian Biotech Industry: Economic Update 2018

    The aim of this report is to present an update of the key facts and figures of the Italian biotech industry.

    The report can be found here.

    See Publication
  • Italy – 2016 Report

    This report presents the key facts and data of the Italian biotech industry and provides a brief analysis of the current context within which Italian companies are operating.

    See Publication
  • BioInItaly Report 2020

    The BioInItaly Report 2020, drafted in collaboration between Assobiotec (Italian Association for the Development of Biotechnology, part of Federchimica) and ENEA (National Agency for New Technologies, Energy and Sustainable Economic Development), offers an update on the current state of the Italian biotech industry.

    The work presents analysis and estimates based on information provided by the firms operating in the sector at the end of 2019, their 2018 financial statements, public data and data from the National Statistical System.

    See Publication